Ongoing Protocols: (update 19/07/2010)
NON-SMALL CELL LUNG CANCER
.
staging
Aster 2
The value of baseline echo-endoscopic mediastinal staging in clinical N1 lung cancer.
PET-CT restaging validationstudy
PET-CT imaging for early response prediction and prognostic value of combined morphometric-pathologic response in mediastinal lymphnodes and primary tumor response on serial PET-CT in patients receiving induction chemotherapy for operable stage IIIA-N2 non-small cell lung cancer
non-advanced
MAGRIT (GSK)
A double blind, randomized, placebo-controlled phase III study to assess the efficacy of recMAGE-A3+ AS15 antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive NSCLC.
PROCLAIM (Lilly)
A phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, locally Advanced, Stage III NSCLC Other than Predominantly squamous Cell Histology.
START (Merck)
A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax in NSCLC subjects with unresectable stage III disease.
advanced first line
CERTO (Merck)
Open-label, randomized, controlled, multicenter Phase II study investigating 2 cilengitide regimens in combination with cetuximab and platinum-based chemotherapy (cisplatin/vinorelbine or cisplatin/gemcitabine) compared to cetuximab and platinum-based chemotherapy alone as first-line treatment for patients with advanced NSCLC.
LUX-Lung 3 (Boehringer)
A randomized, open-label, Phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation
second line
ASA404 (Novartis)
A phase III, randomised, double-blind, placebo-controlled Multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (stage IIIb/IV) NSCLC.
second or third line
BIBW 2992 (Boehringer)
A Phase II single-arm trial of BIBW 2992 (TOVOK) in demographically and genotypically selected NSCLC patients.
Exelixis (Exelixis)
A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors
SMALL CELL LUNG CANCER
.
Extensive first line
AMG (Amgen)
A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination with Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage SCLC.
Second or third line
Exelixis (Exelixis)
A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors
MESOTHELIOMA
SAKK
Neo-adjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy. A randomized multicenter phase II trial.
OTHERS
NELSON
Nederlands-Leuvens Longkanker Screening Onderzoek.
A Randomised Clinical Trial for Lung Cancer Screening in High Risk Subjects 2003-2006
For further information regarding protocols or clinical trial unit description, please contact the datamanagers:
beatrijs.anrijs@uzleuven.be
christel.oyen@uzleuven.be
liesbet.peeters@uzleuven.be
